MDxHealth SA (NASDAQ:MDXH) Sees Significant Growth in Short Interest

MDxHealth SA (NASDAQ:MDXH) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 33,200 shares, an increase of 35.0% from the December 15th total of 24,600 shares. Based on an average daily trading volume, of 125,900 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the shares of the company are short sold.

Hedge Funds Weigh In On MDxHealth

A number of large investors have recently made changes to their positions in MDXH. OneDigital Investment Advisors LLC boosted its holdings in MDxHealth by 15.3% during the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after buying an additional 7,656 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of MDxHealth during the 3rd quarter valued at approximately $208,000. Perkins Capital Management Inc. lifted its position in shares of MDxHealth by 70.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after acquiring an additional 309,500 shares during the period. Finally, MVM Partners LLC boosted its stake in shares of MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after acquiring an additional 150,000 shares in the last quarter.

MDxHealth Price Performance

NASDAQ:MDXH traded down $0.01 during trading hours on Thursday, hitting $1.99. The company’s stock had a trading volume of 81,508 shares, compared to its average volume of 197,071. MDxHealth has a 52-week low of $1.55 and a 52-week high of $4.44. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The business’s 50-day moving average is $2.08 and its two-hundred day moving average is $2.36.

Analysts Set New Price Targets

Several analysts have recently commented on MDXH shares. Lake Street Capital initiated coverage on shares of MDxHealth in a report on Thursday, October 31st. They issued a “buy” rating and a $7.00 target price on the stock. Piper Sandler reduced their price objective on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.